entertainment -WSS

entertainment

author：focus 2025-09-29 01:08:51 - browse：45

A woman walks in San Francisco, with her father who has Alzheimer's – public health and science coverage from STAT — Ben Margot/AP

A host of hurdles are slowing the adoption of the new Alzheimer’s drug Leqembi, experts involved in the treatment of patients said Wednesday, from complicated logistics to the fact that many people don’t recognize that their memory loss is a disease soon enough.

Some patients still grapple with whether they want to be diagnosed, even though a treatment exists, the experts said, speaking during a STAT virtual event.

“Even the word for dementia does not always exist in every culture and in every language,” said Hollis Day, chief of geriatrics at Boston Medical Center and a professor at Boston University’s medical school. “And so just getting people to accept that memory loss is not normal aging necessarily, is a big barrier to getting people into diagnosis early enough to benefit from these treatments.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Young boy dies in trial for Pfizer Duchenne gene therapy

WSS

Young boy dies in trial for Pfizer Duchenne gene therapy

Oral obesity drug from Viking Therapeutics hits key early target

First Opinion on colorectal cancer screening: letter and response

Orchard's therapy for neuron disease in children wins FDA approval

Gut bacteria may contribute to kidney autoimmunity, study finds

Leading voice in opioid treatment defends methadone clinic system

explore

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Medicare details structure of new drug price negotiation program

Readout Newsletter: Geron, Novo Nordisk, WuXi updates

Cancer drug shortages should be causing more outrage

Oral obesity drug from Viking Therapeutics hits key early target

Apple is now the first public company to be valued at $3 trillion

Asbestos, a deadly carcinogen, banned by EPA

Peter Hotez and the public health issue of online harassment

Methadone treatment changes are coming. Do they go far enough?

The high cost of giving birth even with insurance

Bird flu reported in person exposed to presumably infected cattle

hotspot

Readout Newsletter: Geron, Novo Nordisk, WuXi updates

Drug companies' payments and gifts affect physicians' prescribing

Bird flu reported in person exposed to presumably infected cattle

Physicians and social media: If you see something, say something?

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

First Opinion on colorectal cancer screening: letter and response

focus

Wikipedia

focus

Wikipedia